Study type

Study topic

Disease /health condition

Study type

Non-interventional study

Scope of the study

Disease epidemiology
Healthcare resource utilisation

Data collection methods

Secondary data collection
Non-interventional study

Non-interventional study design

Cohort
Cross-sectional
Study drug and medical condition

Medical condition to be studied

Cluster headache
Population studied

Short description of the study population

Adult patients affected by Cluster headache and treated with specific drugs for acute attack associated with a preventive therapy were selected.

Age groups

Adult and elderly population (>18 years)
Adults (18 to < 65 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Elderly (≥ 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)
Study design details

Study design

Retrospective longitudinal cross sectional cohort study.

Main study objective

This study aimed at estimating the treated cluster headache (CH) prevalence and describing prescription patterns and direct costs paid by the Italian National-Health-System.

Setting

In-hospital and local outpatient settings in public and affiliated with SSN facilities.

Summary results

The annual prevalence of CH-treated patients increased from 6.4×100,000 adults in 2013 to 6.7 in 2017. In 2013–2015, 570 patients (80.7% M; mean age 46) treated for CH were found. In 50.4%, the identifying CH treatment was sumatriptan/subcutaneous+verapamil. During follow-up, >1/3 changed the preventive drug and interruption was the most frequent modification, although acute treatments were still prescribed. The mean annual cost/patient ranged from €2,956 to €2,267; pharmaceuticals expenditure represented the 56.4% and 57.3%, respectively.
Documents
Study publications
Insights into real-world treatment of cluster headache through a large Italian …